Table 1 Characteristics of the study population, for the “before” and “after” periods, in the reference centre and in the two peripheral centres
| Â | Overall | Â | Reference centre | Â | Peripheral centres | Â | |||
|---|---|---|---|---|---|---|---|---|---|
| Â | Before | After | p | Before | After | p | Before | After | p |
Number | 306 | 361 | Â | 149 | 193 | Â | 157 | 168 | Â |
Age (year) | 61.5 ± 12.5 | 62.3 ± 13.6 | 0.31 | 60.0 ± 11.9 | 60.4 ± 14.1 | 0.68 | 62.9 ± 12.9 | 64.1 ± 12.9 | 0.30 |
61 [31–88] | 62 [24–89] |  | 61 [31–87] | 61 [26–88] |  | 62 [31–88] | 64 [24–89] |  | |
Hormone status | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Estrogen receptors | Â | Â | 0.40 | Â | Â | 0.51 | Â | Â | 0.04 |
Positive | 264 (86.8) | 318 (89.1) | Â | 131 (89.1) | 164 (86.3) | Â | 133 (84.7) | 154 (92.2) | Â |
Negative | 40 (13.2) | 39 (10.9) | Â | 16 (10.9) | 26 (13.7) | Â | 24 (15.3) | 13 (7.8) | Â |
Progesterone receptors | Â | Â | 0.06 | Â | Â | 0.27 | Â | Â | 0.14 |
Positive | 230 (75.7) | 292 (81.8) | Â | 113 (76.9) | 156 (82.1) | Â | 117 (74.5) | 136 (81.5) | Â |
Negative | 74 (24.3) | 65 (18.2) | Â | 34 (23.1) | 34 (17.9) | Â | 40 (25.5) | 31 (18.6) | Â |
All negative receptors | Â | Â | 0.39 | Â | Â | 0.61 | Â | Â | 0.03 |
Yes | 38 (12.5) | 36 (10.1) | Â | 15 (10.2) | 24 (12.6) | Â | 23 (14.7) | 12 (7.2) | Â |
No | 266 (87.5) | 321 (89.9) | Â | 132 (89.8) | 166 (87.4) | Â | 134 (85.4) | 155 (92.8) | Â |
SBR grade | Â | Â | 0.43 | Â | Â | 0.05 | Â | Â | 0.62 |
1 | 84 (28.3) | 112 (31.8) | Â | 40 (28.4) | 64 (34.2) | Â | 44 (28.2) | 48 (29.1) | Â |
2 | 162 (54.6) | 174 (49.4) | Â | 81 (57.5) | 83 (44.4) | Â | 81 (51.9) | 91 (55.1) | Â |
3 | 51 (17.2) | 66 (18.8) | Â | 20 (14.2) | 40 (21.4) | Â | 31 (19.9) | 26 (15.8) | Â |
Tumor size (mm) | 21.1 ± 16.0 | 20.8 ± 15.6 | 0.97 | 20.2 ± 15.2 | 21.4 ± 15.9 | 0.39 | 21.8 ± 16.8 | 20.0 ± 15.3 | 0.32 |
16 [1–82] | 15 [1–90] |  | 15 [1–82] | 16 [1–90] |  | 17 [1–80] | 15 [3–90] |  | |
TNM classification | Â | Â | Â | Â | Â | Â | Â | Â | Â |
T (mm) | Â | Â | 0.92 | Â | Â | 0.24 | Â | Â | 0.46 |
0 to 19 | 189 (63.6) | 232 (65.0) | Â | 92 (63.0) | 122 (63.9) | Â | 97 (64.2) | 110 (66.3) | Â |
20 to 9 | 87 (29.3) | 101 (28.3) | Â | 46 (31.5) | 54 (28.3) | Â | 41 (27.1) | 47 (28.3) | Â |
≥ 50 | 14 (4.7) | 18 (5.0) |  | 5 (3.4) | 14 (7.3) |  | 9 (6.0) | 4 (2.4) |  |
All size with extension | 7 (2.4) | 6 (1.7) | Â | 3 (2.1) | 1 (0.5) | Â | 4 (2.7) | 5 (3.0) | Â |
N | Â | Â | 0.05 | Â | Â | 0.03 | Â | Â | 0.62 |
0 | 195 (62.3) | 244 (69.1) | Â | 95 (63.8) | 134 (70.9) | Â | 100 (64.9) | 110 (67.1) | Â |
1 to 3 | 81 (27.7) | 90 (25.5) | Â | 41 (27.5) | 45 (23.8) | Â | 40 (26.0) | 45 (27.4) | Â |
4 to 9 | 25 (9.4) | 13 (3.7) | Â | 13 (8.7) | 6 (3.2) | Â | 12 (7.8) | 7 (4.3) | Â |
≥ 10 | 2 (0.6) | 6 (1.7) |  | 0 (0.0) | 4 (2.1) |  | 2 (1.3) | 2 (1.2) |  |
Ten-year risk of progression based on AdjuvantOnline score (%) | Â | Â | 0.92 | Â | Â | 0.37 | Â | Â | 0.69 |
≤ 20 | 82 (29.6) | 94 (29.4) |  | 29 (21.8) | 45 (26.0) |  | 53 (36.8) | 49 (33.3) |  |
]20-40] | 110 (39.7) | 123 (38.4) | Â | 62 (46.6) | 67 (38.7) | Â | 48 (33.3) | 56 (38.1) | Â |
> 40 | 85 (30.7) | 103 (32.2) | Â | 42 (31.6) | 61 (35.3) | Â | 43 (29.9) | 42 (28.6) | Â |